Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer.

Cancer Manag Res · 2013 · PMC3559079 · PMID 23378782

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Subgroup analysis according to molecular and histological characteristics indicated that patients with nonsquamous histology showed a trend in favor of tivantinib plus erlotinib in both overall and progression-free survival.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.